Table of Content
1 EXECUTIVE SUMMARY
2 MARKET DEFINITION, SCOPE AND SEGMENTATION
2.1 PRODUCTS INCLUDED AND EXCLUDED
2.2 SEGMENTATION AXES AND THEIR VALUES
2.3 COUNTRIES AND REGIONAL GROUPINGS
2.4 PRODUCTS APPEARING IN BOTH REPORTS
3 RESEARCH METHODOLOGY AND DATA SOURCES
3.1 SOURCE HIERARCHY AND WHAT EACH SOURCE COVERS
3.2 REPORTED, DERIVED AND ESTIMATED: EX-U.S. AND EX-INDIA
3.3 COVERAGE MAP: EX-U.S. AND EX-INDIA
3.4 ASSUMPTIONS AND LIMITATIONS
4 BIOSIMILARS MARKET OVERVIEW
5 MARKET DYNAMICS
5.1 DRIVERS
5.1.1 LOSS OF EXCLUSIVITY ARRIVING IN WAVES, AND A REGISTER THAT SHOWS THE WAVE ARRIVING
5.1.2 PUBLIC PROCUREMENT DESIGNED TO CONVERT TO THE CHEAPEST COMPLIANT SUPPLIER
5.1.3 HEALTH-SYSTEM SAVINGS AS THE EXPLICIT POLICY OBJECTIVE, QUANTIFIED BY THE BUYER
5.1.4 IN MOST OF THIS GEOGRAPHY THE BIOSIMILAR CREATES THE TREATMENT RATHER THAN REPLACING IT
5.1.5 ONE AUTHORISATION, FIVE NATIONAL PRICES, AND A FILE THAT TRAVELS
5.2 RESTRAINTS
5.2.1 PRICE EROSION THAT IS THE POINT OF THE PRODUCT
5.2.2 NO COMPANY PUBLISHES WHAT IT SELLS, WHERE
5.2.3 CONVERSION THAT VARIES ENORMOUSLY BY MOLECULE, AND NOT IN THE WAY ROUTE OF ADMINISTRATION PREDICTS
5.2.4 EVERY AWARD IS PUBLISHED, SO THE BUYER'S SIDE OF THIS MARKET IS BETTER INFORMED THAN THE SELLER'S
5.3 OPPORTUNITIES
5.3.1 THE MOLECULES THAT HAVE NOT CONVERTED YET, IN THE MARKETS THAT HAVE SHOWN THEY CAN
5.3.2 EMERGING MARKETS THAT BUY ON PRICE AND PUBLISH WHAT THEY PAID
5.3.3 THE HOSPITAL CHANNEL, WHERE THE VOLUME IS AND THE PUBLIC DATA MOSTLY IS NOT
5.3.4 THE PRESENTATION HALF OF A MOLECULE THAT HAS ALREADY CONVERTED
5.4 CHALLENGES
5.4.1 A MARKET THAT CANNOT BE SIZED FROM PUBLIC SOURCES, AND THE EVIDENCE FOR SAYING SO
5.4.2 TWENTY-SEVEN MOLECULES, THIRTY-SEVEN SUPPLIERS, AND NO TWO MARKETS ALIKE
5.4.3 BRAZIL AND CHILE ARE WHAT CAN BE OBSERVED, AND NEITHER SEES ITS WHOLE COUNTRY
5.4.4 WHETHER A PRODUCT IS ON SALE IN A COUNTRY CANNOT BE READ OFF THE EUROPEAN REGISTER
5.5 EMERGING TRENDS IN THE INDUSTRY
5.5.1 THE WAVE MOVING FROM INTRAVENOUS ONCOLOGY INTO SUBCUTANEOUS IMMUNOLOGY
5.5.2 CONSOLIDATION OF SUPPLY INTO A SMALL NUMBER OF INTEGRATED BIOLOGICS MANUFACTURERS
5.5.3 BUYERS PUBLISHING CONVERSION DATA AS AN INSTRUMENT OF POLICY
5.5.4 TENDER WINS BECOMING THE GROWTH LINE IN SUPPLIERS' OWN ACCOUNTS
5.5.5 THE REFERENCE PRODUCT MOVING TO A PRESENTATION NO BIOSIMILAR HAS YET COPIED
5.6 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES
5.7 PORTER'S FIVE FORCES ANALYSIS
5.8 PESTEL ANALYSIS
5.9 SWOT ANALYSIS
6 PRICING ANALYSIS
6.1 PRICE BY TYPE: LIST, EX-FACTORY, REIMBURSED, TENDER, RETAIL
6.2 PRICE PER STANDARD UNIT BY COUNTRY
6.3 PRICE MOVEMENT, 2018-2025
6.4 PRICE OUTLOOK, 2026-2033
6.5 PRICE IN LOCAL CURRENCY AGAINST USD, WITH STATED RATE
6.6 CONSTANT-CURRENCY PRICE MOVEMENT: ARGENTINA, TURKEY, EGYPT
7 TENDER AND PUBLIC PROCUREMENT ANALYSIS
7.1 AWARDED TENDERS BY COUNTRY, BUYER AND WINNING COMPANY
7.2 AWARDED VOLUME AND PRICE BY MOLECULE
7.3 PUBLIC AGAINST PRIVATE CHANNEL MIX
7.4 TENDER PRICE AGAINST LIST PRICE BY COUNTRY
7.5 CHANNEL COVERAGE AND WHAT EACH SOURCE EXCLUDES
8 PRODUCT AND MOLECULE LANDSCAPE
8.1 PRODUCT UNIVERSE BY COUNTRY: BRAND, MOLECULE, STRENGTH, FORM
8.2 MARKETING AUTHORISATION HOLDER, MANUFACTURER, PARTNER, DISTRIBUTOR
8.3 APPROVAL AND LAUNCH DATE BY COUNTRY
8.4 MARKETED AGAINST REGISTERED-NOT-MARKETED
9 REGULATORY FRAMEWORK AND APPROVAL PATHWAYS
9.1 APPROVAL PATHWAY AND GOVERNING BODY BY COUNTRY
9.2 REGISTRATION REQUIREMENTS AND TYPICAL TIMELINES
9.3 PRICING AND REIMBURSEMENT CONTROL BY COUNTRY
10 BIOSIMILAR PENETRATION AGAINST THE ORIGINATOR
10.1 PENETRATION BY VALUE AND VOLUME, BY MOLECULE AND COUNTRY
10.2 ORIGINATOR AGAINST BIOSIMILAR PRICE AND DISCOUNT
10.3 DISCOUNT AT LAUNCH AGAINST CURRENT DISCOUNT
10.4 SHARE MOVEMENT SINCE BIOSIMILAR ENTRY
10.5 ROWS WITH NO BRAND IDENTIFIED, BY MOLECULE AND COUNTRY
11 COUNTRY-BY-MOLECULE MARKET MAP
11.1 COMPANIES AND BRANDS PRESENT PER CELL
12 BIOSIMILARS MARKET, BY MOLECULE, 2018–2033 (USD MILLION)
12.1 OVERVIEW
12.2 DENOSUMAB
12.3 AFLIBERCEPT
12.4 USTEKINUMAB
12.5 ADALIMUMAB
12.6 PEGFILGRASTIM
12.7 BEVACIZUMAB
12.8 RANIBIZUMAB
12.9 TRASTUZUMAB
12.1 FILGRASTIM
12.11 RITUXIMAB
12.12 TERIPARATIDE
12.13 ETANERCEPT
12.14 OCILIZUMAB
12.15 EPOETIN ALFA
12.16 INFLIXIMAB
12.17 INSULIN ASPART
12.18 INSULIN GLARGINE
12.19 ECULIZUMAB
12.2 EPOETIN ZETA
12.21 FOLLITROPIN ALFA
12.22 GOLIMUMAB
12.23 INSULIN LISPRO
12.24 ENOXAPARIN SODIUM
12.25 NATALIZUMAB
12.26 OMALIZUMAB
12.27 PERTUZUMAB
12.28 SOMATROPIN
13 BIOSIMILARS MARKET, BY THERAPEUTIC GROUP, 2018–2033 (USD MILLION)
13.1 OVERVIEW
13.2 IMMUNOLOGY AND INFLAMMATION
13.3 ONCOLOGY
13.4 OPHTHALMOLOGY
13.5 HAEMATOLOGY AND SUPPORTIVE CARE
13.6 BONE AND METABOLIC
13.7 DIABETES
13.8 ENDOCRINOLOGY AND FERTILITY
13.9 RESPIRATORY AND ALLERGY
14 BIOSIMILARS MARKET, BY MARKET STATUS, 2018–2033 (USD MILLION)
14.1 OVERVIEW
14.2 MARKETED
14.3 APPROVED NOT LAUNCHED
14.4 FILED
14.5 NOT PRESENT
14.6 NOT KNOWN
15 BIOSIMILARS MARKET, BY CHANNEL, 2018–2033 (USD MILLION)
15.1 OVERVIEW
15.2 PUBLIC TENDER
15.2.1 DENOSUMAB
15.2.2 AFLIBERCEPT
15.2.3 USTEKINUMAB
15.2.4 ADALIMUMAB
15.2.5 PEGFILGRASTIM
15.2.6 BEVACIZUMAB
15.2.7 RANIBIZUMAB
15.2.8 TRASTUZUMAB
15.2.9 FILGRASTIM
15.2.10 RITUXIMAB
15.2.11 TERIPARATIDE
15.2.12 ETANERCEPT
15.2.13 TOCILIZUMAB
15.2.14 EPOETIN ALFA
15.2.15 INFLIXIMAB
15.2.16 INSULIN ASPART
15.2.17 INSULIN GLARGINE
15.2.18 ECULIZUMAB
15.2.19 EPOETIN ZETA
15.2.20 FOLLITROPIN ALFA
15.2.21 GOLIMUMAB
15.2.22 INSULIN LISPRO
15.2.23 ENOXAPARIN SODIUM
15.2.24 NATALIZUMAB
15.2.25 OMALIZUMAB
15.2.26 PERTUZUMAB
15.2.27 SOMATROPIN
15.3 HOSPITAL
15.3.1 DENOSUMAB
15.3.2 AFLIBERCEPT
15.3.3 USTEKINUMAB
15.3.4 ADALIMUMAB
15.3.5 PEGFILGRASTIM
15.3.6 BEVACIZUMAB
15.3.7 RANIBIZUMAB
15.3.8 TRASTUZUMAB
15.3.9 FILGRASTIM
15.3.10 RITUXIMAB
15.3.11 TERIPARATIDE
15.3.12 ETANERCEPT
15.3.13 TOCILIZUMAB
15.3.14 EPOETIN ALFA
15.3.15 INFLIXIMAB
15.3.16 INSULIN ASPART
15.3.17 INSULIN GLARGINE
15.3.18 ECULIZUMAB
15.3.19 EPOETIN ZETA
15.3.20 FOLLITROPIN ALFA
15.3.21 GOLIMUMAB
15.3.22 INSULIN LISPRO
15.3.23 ENOXAPARIN SODIUM
15.3.24 NATALIZUMAB
15.3.25 OMALIZUMAB
15.3.26 PERTUZUMAB
15.3.27 SOMATROPIN
15.4 RETAIL PHARMACY
15.4.1 DENOSUMAB
15.4.2 AFLIBERCEPT
15.4.3 USTEKINUMAB
15.4.4 ADALIMUMAB
15.4.5 PEGFILGRASTIM
15.4.6 BEVACIZUMAB
15.4.7 RANIBIZUMAB
15.4.8 TRASTUZUMAB
15.4.9 FILGRASTIM
15.4.10 RITUXIMAB
15.4.11 TERIPARATIDE
15.4.12 ETANERCEPT
15.4.13 TOCILIZUMAB
15.4.14 EPOETIN ALFA
15.4.15 INFLIXIMAB
15.4.16 INSULIN ASPART
15.4.17 INSULIN GLARGINE
15.4.18 ECULIZUMAB
15.4.19 EPOETIN ZETA
15.4.20 FOLLITROPIN ALFA
15.4.21 GOLIMUMAB
15.4.22 INSULIN LISPRO
15.4.23 ENOXAPARIN SODIUM
15.4.24 NATALIZUMAB
15.4.25 OMALIZUMAB
15.4.26 PERTUZUMAB
15.4.27 SOMATROPIN
15.5 PRIVATE MARKET
15.5.1 DENOSUMAB
15.5.2 AFLIBERCEPT
15.5.3 USTEKINUMAB
15.5.4 ADALIMUMAB
15.5.5 PEGFILGRASTIM
15.5.6 BEVACIZUMAB
15.5.7 RANIBIZUMAB
15.5.8 TRASTUZUMAB
15.5.9 FILGRASTIM
15.5.10 RITUXIMAB
15.5.11 TERIPARATIDE
15.5.12 ETANERCEPT
15.5.13 TOCILIZUMAB
15.5.14 EPOETIN ALFA
15.5.15 INFLIXIMAB
15.5.16 INSULIN ASPART
15.5.17 INSULIN GLARGINE
15.5.18 ECULIZUMAB
15.5.19 EPOETIN ZETA
15.5.20 FOLLITROPIN ALFA
15.5.21 GOLIMUMAB
15.5.22 INSULIN LISPRO
15.5.23 ENOXAPARIN SODIUM
15.5.24 NATALIZUMAB
15.5.25 OMALIZUMAB
15.5.26 PERTUZUMAB
15.5.27 SOMATROPIN
16 BIOSIMILARS MARKET, BY GEOGRAPHY, 2018–2033 (USD MILLION)
16.1 OVERVIEW
16.2 GLOBAL
16.2.1 EU-5
16.2.1.1 GERMANY
16.2.1.2 FRANCE
16.2.1.3 ITALY
16.2.1.4 SPAIN
16.2.1.5 UNITED KINGDOM
16.2.2 LATIN AMERICA
16.2.2.1 BRAZIL
16.2.2.2 MEXICO
16.2.2.3 ARGENTINA
16.2.2.4 COLOMBIA
16.2.2.5 CHILE
16.2.3 CHINA
16.2.3.1 CHINA
16.2.4 SOUTHEAST ASIA
16.2.4.1 INDONESIA
16.2.4.2 THAILAND
16.2.4.3 VIETNAM
16.2.4.4 PHILIPPINES
16.2.4.5 MALAYSIA
16.2.4.6 SINGAPORE
16.2.5 MENA
16.2.5.1 SAUDI ARABIA
16.2.5.2 UNITED ARAB EMIRATES
16.2.5.3 EGYPT
16.2.5.4 TURKEY
17 COMPETITIVE LANDSCAPE
17.1 COMPANY SHARE BY VALUE AND VOLUME, 2025
17.2 COMPANY RANKING BY COUNTRY AND REGION
17.3 NUMBER OF MARKETED PRODUCTS PER COMPANY
17.4 SALES GROWTH BY COMPANY
18 COMPANY PROFILES
18.1 COMPANIES NAMED AS MANDATORY
18.1.1 SANDOZ
18.1.1.1 COMPANY OVERVIEW
18.1.1.2 REVENUE ANALYSIS
18.1.1.3 GEOGRAPHIC PRESENCE
18.1.1.4 M&A
18.1.1.5 PRODUCTION CAPACITY EXPANSION
18.1.1.6 PRODUCT LAUNCHES
18.1.1.7 OTHERS
18.1.1.8 PRODUCT PORTFOLIO
18.1.1.9 RECENT DEVELOPMENTS
18.1.2 CELLTRION
18.1.2.1 COMPANY OVERVIEW
18.1.2.2 REVENUE ANALYSIS
18.1.2.3 GEOGRAPHIC PRESENCE
18.1.2.4 PRODUCT LAUNCHES
18.1.2.5 OTHERS
18.1.2.6 PRODUCT PORTFOLIO
18.1.2.7 RECENT DEVELOPMENTS
18.1.3 BIOCON BIOLOGICS
18.1.3.1 COMPANY OVERVIEW
18.1.3.2 REVENUE ANALYSIS
18.1.3.3 GEOGRAPHIC PRESENCE
18.1.3.4 M&A
18.1.3.5 OTHERS
18.1.3.6 PRODUCT PORTFOLIO
18.1.3.7 RECENT DEVELOPMENTS
18.1.4 AMGEN
18.1.4.1 COMPANY OVERVIEW
18.1.4.2 REVENUE ANALYSIS
18.1.4.3 GEOGRAPHIC PRESENCE
18.1.4.4 OTHERS
18.1.4.5 PRODUCT PORTFOLIO
18.1.4.6 RECENT DEVELOPMENTS
18.1.5 TEVA
18.1.5.1 COMPANY OVERVIEW
18.1.5.2 REVENUE ANALYSIS
18.1.5.3 GEOGRAPHIC PRESENCE
18.1.5.4 PRODUCT LAUNCHES
18.1.5.5 OTHERS
18.1.5.6 PRODUCT PORTFOLIO
18.1.5.7 RECENT DEVELOPMENTS
18.1.6 ORGANON
18.1.6.1 COMPANY OVERVIEW
18.1.6.2 REVENUE ANALYSIS
18.1.6.3 GEOGRAPHIC PRESENCE
18.1.6.4 PRODUCT LAUNCHES
18.1.6.5 OTHERS
18.1.6.6 PRODUCT PORTFOLIO
18.1.6.7 RECENT DEVELOPMENTS
18.2 OTHER COMPANIES COVERED
18.2.1 SAMSUNG BIOEPIS
18.2.1.1 COMPANY OVERVIEW
18.2.1.2 REVENUE ANALYSIS
18.2.1.3 GEOGRAPHIC PRESENCE
18.2.1.4 COLLABORATION
18.2.1.5 OTHERS
18.2.1.6 PRODUCT PORTFOLIO
18.2.1.7 RECENT DEVELOPMENTS
18.2.2 FRESENIUS KABI
18.2.2.1 COMPANY OVERVIEW
18.2.2.2 REVENUE ANALYSIS
18.2.2.3 GEOGRAPHIC PRESENCE
18.2.2.4 COLLABORATION
18.2.2.5 PRODUCT LAUNCHES
18.2.2.6 OTHERS
18.2.2.7 PRODUCT PORTFOLIO
18.2.2.8 RECENT DEVELOPMENTS
18.2.3 STADA
18.2.3.1 COMPANY OVERVIEW
18.2.3.2 REVENUE ANALYSIS
18.2.3.3 GEOGRAPHIC PRESENCE
18.2.3.4 COLLABORATION
18.2.3.5 OTHERS
18.2.3.6 PRODUCT PORTFOLIO
18.2.3.7 RECENT DEVELOPMENTS
18.2.4 ACCORD HEALTHCARE
18.2.4.1 COMPANY OVERVIEW
18.2.4.2 REVENUE ANALYSIS
18.2.4.3 GEOGRAPHIC PRESENCE
18.2.4.4 PRODUCT ACQUISITION
18.2.4.5 OTHERS
18.2.4.6 PRODUCT PORTFOLIO
18.2.4.7 RECENT DEVELOPMENTS
18.2.5 VIATRIS
18.2.5.1 COMPANY OVERVIEW
18.2.5.2 REVENUE ANALYSIS
18.2.5.3 GEOGRAPHIC PRESENCE
18.2.5.4 M&A
18.2.5.5 OTHERS
18.2.5.6 PRODUCT PORTFOLIO
18.2.5.7 RECENT DEVELOPMENTS
18.2.6 PFIZER
18.2.6.1 COMPANY OVERVIEW
18.2.6.2 REVENUE ANALYSIS
18.2.6.3 GEOGRAPHIC PRESENCE
18.2.6.4 OTHERS
18.2.6.5 PRODUCT PORTFOLIO
18.2.6.6 RECENT DEVELOPMENTS
18.2.7 COHERUS
18.2.7.1 COMPANY OVERVIEW
18.2.7.2 GEOGRAPHIC PRESENCE
18.2.7.3 MAJOR DEALS
18.2.7.4 M&A
18.2.7.5 OTHERS
18.2.7.6 PRODUCT PORTFOLIO
18.2.7.7 RECENT DEVELOPMENTS
18.2.8 GAN & LEE
18.2.8.1 COMPANY OVERVIEW
18.2.8.2 REVENUE ANALYSIS
18.2.8.3 GEOGRAPHIC PRESENCE
18.2.8.4 PRODUCTION CAPACITY EXPANSION
18.2.8.5 OTHERS
18.2.8.6 PRODUCT PORTFOLIO
18.2.8.7 RECENT DEVELOPMENTS
19 COMMERCIAL PRESENCE AND ROUTE TO MARKET
19.1 DIRECT AGAINST PARTNER-LED MODEL BY COUNTRY
19.2 NAMED DISTRIBUTORS AND MARKETS HANDLED
19.3 FIELD FORCE SIZE, WHERE OBTAINABLE
20 COUNTRY DEEP-DIVES
21 DELIVERABLES, SOURCES AND LIMITATIONS
21.1 ACCOMPANYING DATABASES AND THEIR CONTENTS
21.2 SOURCES BY CLASS, WITH COVERAGE AND DATE ACCESSED
21.3 WHAT COULD NOT BE OBTAINED, AND WHY
List of Table
TABLE 1 IMPACT OF EACH FORCE, BY SEGMENT
TABLE 2 PESTEL ANALYSIS
TABLE 3 SWOT: STRENGTHS AND WEAKNESSES
TABLE 4 SWOT: OPPORTUNITIES AND THREATS
TABLE 5 PRICE BY TYPE: LIST, EX-FACTORY, REIMBURSED, TENDER, RETAIL
TABLE 6 PRICE PER STANDARD UNIT BY COUNTRY
TABLE 7 OBSERVED MONTHLY PURCHASING RECORD, AS PUBLISHED
TABLE 8 PRICE IN LOCAL CURRENCY AGAINST USD, WITH STATED RATE
TABLE 9 APPROVAL AND LAUNCH DATE BY COUNTRY
TABLE 10 MARKETED AGAINST REGISTERED-NOT-MARKETED
TABLE 11 APPROVAL PATHWAY AND GOVERNING BODY, BY COUNTRY
TABLE 12 WHO DECIDES WHAT A BIOSIMILAR IS PAID, AND HOW
TABLE 13 PENETRATION BY VALUE AND VOLUME, BY MOLECULE AND COUNTRY
TABLE 14 ORIGINATOR AGAINST BIOSIMILAR PRICE AND DISCOUNT
TABLE 15 DISCOUNT AT FIRST AND LATEST OBSERVATION, BY MOLECULE
TABLE 16 BIOSIMILAR SHARE OF PACKS, FIRST AND LATEST OBSERVATION
TABLE 17 AWARDED LINES WITH NO BRAND RESOLVED
TABLE 18 COMPANIES AND BRANDS PRESENT PER CELL
TABLE 19 BIOSIMILARS MARKET, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 20 BIOSIMILARS MARKET, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 21 BIOSIMILARS MARKET, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 22 BIOSIMILARS MARKET, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 23 BIOSIMILARS MARKET, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 24 BIOSIMILARS MARKET, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 25 BIOSIMILARS MARKET, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 26 BIOSIMILARS MARKET, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 27 PUBLIC TENDER, BY TYPE, 2018-2025 (USD MILLION)
TABLE 28 PUBLIC TENDER, BY TYPE, 2026-2033 (USD MILLION)
TABLE 29 HOSPITAL, BY TYPE, 2018-2025 (USD MILLION)
TABLE 30 HOSPITAL, BY TYPE, 2026-2033 (USD MILLION)
TABLE 31 RETAIL PHARMACY, BY TYPE, 2018-2025 (USD MILLION)
TABLE 32 RETAIL PHARMACY, BY TYPE, 2026-2033 (USD MILLION)
TABLE 33 PRIVATE MARKET, BY TYPE, 2018-2025 (USD MILLION)
TABLE 34 PRIVATE MARKET, BY TYPE, 2026-2033 (USD MILLION)
TABLE 35 BIOSIMILARS MARKET, BY GEOGRAPHY, 2018-2025 (USD MILLION)
TABLE 36 BIOSIMILARS MARKET, BY GEOGRAPHY, 2026-2033 (USD MILLION)
TABLE 37 EU-5, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 38 EU-5, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 39 EU-5, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 40 EU-5, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 41 EU-5, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 42 EU-5, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 43 EU-5, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 44 EU-5, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 45 EU-5, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 46 EU-5, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 47 GERMANY, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 48 GERMANY, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 49 GERMANY, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 50 GERMANY, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 51 GERMANY, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 52 GERMANY, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 53 GERMANY, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 54 GERMANY, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 55 FRANCE, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 56 FRANCE, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 57 FRANCE, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 58 FRANCE, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 59 FRANCE, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 60 FRANCE, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 61 FRANCE, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 62 FRANCE, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 63 ITALY, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 64 ITALY, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 65 ITALY, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 66 ITALY, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 67 ITALY, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 68 ITALY, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 69 ITALY, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 70 ITALY, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 71 SPAIN, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 72 SPAIN, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 73 SPAIN, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 74 SPAIN, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 75 SPAIN, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 76 SPAIN, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 77 SPAIN, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 78 SPAIN, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 79 UNITED KINGDOM, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 80 UNITED KINGDOM, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 81 UNITED KINGDOM, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 82 UNITED KINGDOM, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 83 UNITED KINGDOM, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 84 UNITED KINGDOM, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 85 UNITED KINGDOM, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 86 UNITED KINGDOM, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 87 LATIN AMERICA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 88 LATIN AMERICA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 89 LATIN AMERICA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 90 LATIN AMERICA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 91 LATIN AMERICA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 92 LATIN AMERICA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 93 LATIN AMERICA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 94 LATIN AMERICA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 95 LATIN AMERICA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 96 LATIN AMERICA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 97 BRAZIL, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 98 BRAZIL, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 99 BRAZIL, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 100 BRAZIL, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 101 BRAZIL, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 102 BRAZIL, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 103 BRAZIL, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 104 BRAZIL, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 105 MEXICO, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 106 MEXICO, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 107 MEXICO, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 108 MEXICO, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 109 MEXICO, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 110 MEXICO, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 111 MEXICO, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 112 MEXICO, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 113 ARGENTINA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 114 ARGENTINA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 115 ARGENTINA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 116 ARGENTINA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 117 ARGENTINA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 118 ARGENTINA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 119 ARGENTINA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 120 ARGENTINA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 121 COLOMBIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 122 COLOMBIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 123 COLOMBIA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 124 COLOMBIA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 125 COLOMBIA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 126 COLOMBIA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 127 COLOMBIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 128 COLOMBIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 129 CHILE, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 130 CHILE, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 131 CHILE, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 132 CHILE, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 133 CHILE, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 134 CHILE, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 135 CHILE, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 136 CHILE, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 137 CHINA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 138 CHINA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 139 CHINA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 140 CHINA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 141 CHINA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 142 CHINA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 143 CHINA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 144 CHINA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 145 CHINA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 146 CHINA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 147 CHINA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 148 CHINA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 149 CHINA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 150 CHINA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 151 CHINA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 152 CHINA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 153 CHINA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 154 CHINA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 155 SOUTHEAST ASIA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 156 SOUTHEAST ASIA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 157 SOUTHEAST ASIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 158 SOUTHEAST ASIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 159 SOUTHEAST ASIA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 160 SOUTHEAST ASIA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 161 SOUTHEAST ASIA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 162 SOUTHEAST ASIA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 163 SOUTHEAST ASIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 164 SOUTHEAST ASIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 165 INDONESIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 166 INDONESIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 167 INDONESIA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 168 INDONESIA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 169 INDONESIA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 170 INDONESIA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 171 INDONESIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 172 INDONESIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 173 THAILAND, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 174 THAILAND, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 175 THAILAND, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 176 THAILAND, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 177 THAILAND, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 178 THAILAND, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 179 THAILAND, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 180 THAILAND, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 181 VIETNAM, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 182 VIETNAM, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 183 VIETNAM, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 184 VIETNAM, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 185 VIETNAM, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 186 VIETNAM, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 187 VIETNAM, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 188 VIETNAM, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 189 PHILIPPINES, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 190 PHILIPPINES, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 191 PHILIPPINES, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 192 PHILIPPINES, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 193 PHILIPPINES, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 194 PHILIPPINES, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 195 PHILIPPINES, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 196 PHILIPPINES, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 197 MALAYSIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 198 MALAYSIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 199 MALAYSIA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 200 MALAYSIA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 201 MALAYSIA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 202 MALAYSIA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 203 MALAYSIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 204 MALAYSIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 205 SINGAPORE, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 206 SINGAPORE, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 207 SINGAPORE, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 208 SINGAPORE, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 209 SINGAPORE, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 210 SINGAPORE, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 211 SINGAPORE, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 212 SINGAPORE, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 213 MENA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 214 MENA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 215 MENA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 216 MENA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 217 MENA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 218 MENA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 219 MENA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 220 MENA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 221 MENA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 222 MENA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 223 SAUDI ARABIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 224 SAUDI ARABIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 225 SAUDI ARABIA, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 226 SAUDI ARABIA, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 227 SAUDI ARABIA, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 228 SAUDI ARABIA, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 229 SAUDI ARABIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 230 SAUDI ARABIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 231 UNITED ARAB EMIRATES, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 232 UNITED ARAB EMIRATES, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 233 UNITED ARAB EMIRATES, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 234 UNITED ARAB EMIRATES, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 235 UNITED ARAB EMIRATES, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 236 UNITED ARAB EMIRATES, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 237 UNITED ARAB EMIRATES, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 238 UNITED ARAB EMIRATES, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 239 EGYPT, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 240 EGYPT, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 241 EGYPT, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 242 EGYPT, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 243 EGYPT, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 244 EGYPT, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 245 EGYPT, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 246 EGYPT, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 247 TURKEY, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 248 TURKEY, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 249 TURKEY, BY THERAPEUTIC GROUP, 2018-2025 (USD MILLION)
TABLE 250 TURKEY, BY THERAPEUTIC GROUP, 2026-2033 (USD MILLION)
TABLE 251 TURKEY, BY MARKET STATUS, 2018-2025 (USD MILLION)
TABLE 252 TURKEY, BY MARKET STATUS, 2026-2033 (USD MILLION)
TABLE 253 TURKEY, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 254 TURKEY, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 255 COMPANY SHARE BY VALUE AND VOLUME, 2025
TABLE 256 EU-5: COMPANY SHARE BY VOLUME, 2025
TABLE 257 LATIN AMERICA: COMPANY SHARE BY VOLUME, 2025
TABLE 258 SOUTHEAST ASIA: COMPANY SHARE BY VOLUME, 2025
TABLE 259 MENA: COMPANY SHARE BY VOLUME, 2025
TABLE 260 CHINA: COMPANY SHARE BY VOLUME, 2025
TABLE 261 EU-5: COMPANY SHARE BY VALUE, 2025
TABLE 262 LATIN AMERICA: COMPANY SHARE BY VALUE, 2025
TABLE 263 SOUTHEAST ASIA: COMPANY SHARE BY VALUE, 2025
TABLE 264 MENA: COMPANY SHARE BY VALUE, 2025
TABLE 265 CHINA: COMPANY SHARE BY VALUE, 2025
TABLE 266 NUMBER OF MARKETED PRODUCTS PER COMPANY
TABLE 267 SALES GROWTH BY COMPANY
TABLE 268 SANDOZ: PRODUCT PORTFOLIO
TABLE 269 SANDOZ: RECENT DEVELOPMENTS
TABLE 270 CELLTRION: PRODUCT PORTFOLIO
TABLE 271 CELLTRION: RECENT DEVELOPMENTS
TABLE 272 BIOCON BIOLOGICS: PRODUCT PORTFOLIO
TABLE 273 BIOCON BIOLOGICS: RECENT DEVELOPMENTS
TABLE 274 AMGEN: PRODUCT PORTFOLIO
TABLE 275 AMGEN: RECENT DEVELOPMENTS
TABLE 276 TEVA: PRODUCT PORTFOLIO
TABLE 277 TEVA: RECENT DEVELOPMENTS
TABLE 278 ORGANON: PRODUCT PORTFOLIO
TABLE 279 ORGANON: RECENT DEVELOPMENTS
TABLE 280 SAMSUNG BIOEPIS: PRODUCT PORTFOLIO
TABLE 281 SAMSUNG BIOEPIS: RECENT DEVELOPMENTS
TABLE 282 FRESENIUS KABI: PRODUCT PORTFOLIO
TABLE 283 FRESENIUS KABI: RECENT DEVELOPMENTS
TABLE 284 STADA: PRODUCT PORTFOLIO
TABLE 285 STADA: RECENT DEVELOPMENTS
TABLE 286 ACCORD HEALTHCARE: PRODUCT PORTFOLIO
TABLE 287 ACCORD HEALTHCARE: RECENT DEVELOPMENTS
TABLE 288 VIATRIS: PRODUCT PORTFOLIO
TABLE 289 VIATRIS: RECENT DEVELOPMENTS
TABLE 290 PFIZER: PRODUCT PORTFOLIO
TABLE 291 PFIZER: RECENT DEVELOPMENTS
TABLE 292 COHERUS: PRODUCT PORTFOLIO
TABLE 293 COHERUS: RECENT DEVELOPMENTS
TABLE 294 GAN & LEE: PRODUCT PORTFOLIO
TABLE 295 GAN & LEE: RECENT DEVELOPMENTS
TABLE 296 NAMED DISTRIBUTORS AND WHOLESALERS, AND HOW MANY EACH COMPANY USES
TABLE 297 SOURCES BY CLASS, WITH COVERAGE AND DATE ACCESSED
TABLE 298 WHAT COULD NOT BE OBTAINED, AND WHY
List of Figure
FIGURE 1 EX-U.S. AND EX-INDIA BIOSIMILARS MARKET, 2018-2033 (USD MILLION)
FIGURE 2 EX-U.S. AND EX-INDIA BIOSIMILARS MARKET: SEGMENTATION AT A GLANCE, 2025
FIGURE 3 EX-U.S. AND EX-INDIA BIOSIMILARS MARKET: DRIVERS IMPACT ANALYSIS
FIGURE 4 EX-U.S. AND EX-INDIA BIOSIMILARS MARKET: PORTER'S FIVE FORCES
FIGURE 5 EX-U.S. AND EX-INDIA BIOSIMILARS MARKET: PESTLE ANALYSIS
FIGURE 6 EX-U.S. AND EX-INDIA BIOSIMILARS: SWOT ANALYSIS
FIGURE 7 BIOSIMILARS MARKET, BY MOLECULE: KEY FINDINGS
FIGURE 8 BIOSIMILARS MARKET, BY MOLECULE, 2025
FIGURE 9 EX-U.S. AND EX-INDIA BIOSIMILARS MARKET, BY MOLECULE, 2033 (USD MILLION)
FIGURE 10 BIOSIMILARS MARKET, BY THERAPEUTIC GROUP: KEY FINDINGS
FIGURE 11 BIOSIMILARS MARKET, BY THERAPEUTIC GROUP, 2025
FIGURE 12 BIOSIMILARS MARKET, BY MARKET STATUS: KEY FINDINGS
FIGURE 13 BIOSIMILARS MARKET, BY MARKET STATUS, 2025
FIGURE 14 BIOSIMILARS MARKET, BY CHANNEL: KEY FINDINGS
FIGURE 15 BIOSIMILARS MARKET, BY CHANNEL, 2025
FIGURE 16 BIOSIMILARS MARKET, BY GEOGRAPHY: KEY FINDINGS
FIGURE 17 BIOSIMILARS MARKET, BY GEOGRAPHY, 2025
FIGURE 18 EU-5, BY COUNTRY, 2025
FIGURE 19 LATIN AMERICA, BY COUNTRY, 2025
FIGURE 20 CHINA, BY COUNTRY, 2025
FIGURE 21 SOUTHEAST ASIA, BY COUNTRY, 2025
FIGURE 22 MENA, BY COUNTRY, 2025
FIGURE 23 SANDOZ, SHARE OF THE EX-U.S. AND EX-INDIA BIOSIMILARS MARKET, 2025
FIGURE 24 SANDOZ: COMPANY SNAPSHOT
FIGURE 25 CELLTRION, SHARE OF THE EX-U.S. AND EX-INDIA BIOSIMILARS MARKET, 2025
FIGURE 26 CELLTRION: COMPANY SNAPSHOT
FIGURE 27 BIOCON BIOLOGICS, SHARE OF THE EX-U.S. AND EX-INDIA BIOSIMILARS MARKET, 2025
FIGURE 28 BIOCON BIOLOGICS: COMPANY SNAPSHOT
FIGURE 29 AMGEN, SHARE OF THE EX-U.S. AND EX-INDIA BIOSIMILARS MARKET, 2025
FIGURE 30 AMGEN: COMPANY SNAPSHOT
FIGURE 31 TEVA: COMPANY SNAPSHOT
FIGURE 32 ORGANON, SHARE OF THE EX-U.S. AND EX-INDIA BIOSIMILARS MARKET, 2025
FIGURE 33 ORGANON: COMPANY SNAPSHOT
FIGURE 34 SAMSUNG BIOEPIS, SHARE OF THE EX-U.S. AND EX-INDIA BIOSIMILARS MARKET, 2025
FIGURE 35 SAMSUNG BIOEPIS: COMPANY SNAPSHOT
FIGURE 36 FRESENIUS KABI: COMPANY SNAPSHOT
FIGURE 37 STADA: COMPANY SNAPSHOT
FIGURE 38 ACCORD HEALTHCARE: COMPANY SNAPSHOT
FIGURE 39 VIATRIS: COMPANY SNAPSHOT
FIGURE 40 PFIZER: COMPANY SNAPSHOT
FIGURE 41 COHERUS: COMPANY SNAPSHOT
FIGURE 42 GAN & LEE: COMPANY SNAPSHOT
